NIH振兴法案实施后神经肿瘤学临床试验中女性和少数族裔入组的人群研究
这项登记研究分析了2000年1月至2019年12月发表的662项神经上皮性中枢神经系统肿瘤治疗性临床试验,共49907名参与者。结果显示,男性占62.5%、女性占37.5%(P<.0001),白人、亚裔、黑人和西班牙裔分别占91.7%、1.5%、2.6%和1.7%;与死亡率相比,黑人、西班牙裔和亚裔入组不足。作者结论认为,振兴法案实施后女性和少数族裔在治疗性临床试验中仍代表性不足,但入组随时间有所改善。
要点
- 662项试验共49907名参与者,男性62.5% vs 女性37.5%(P<.0001)。
- 白人、亚裔、黑人和西班牙裔分别占试验参与者的91.7%、1.5%、2.6%和1.7%。
- 与死亡率相比,黑人、西班牙裔和亚裔入组不足,白人入组超过预期死亡率。
核心结论
- 振兴法案实施后,女性和少数族裔在神经上皮性肿瘤治疗性临床试验中相对于疾病发病率和死亡率仍代表性不足,但研究入组随时间有所改善。
研究设计与样本
- 登记研究,分析2000年1月至2019年12月发表的经世界卫生组织定义的神经上皮性中枢神经系统肿瘤临床试验。
- 研究参与者来自PubMed和ClinicalTrials.gov,发病分析人群数据来自CBTRUS,死亡分析使用SEER-18 Incidence-Based Mortality数据。
- 共纳入662项已发表的临床试验,涉及49907名参与者。
- 数据分析使用描述性统计、Fisher精确检验和χ²检验。
主要发现
- 在662项试验的49907名参与者中,男性占62.5%,女性占37.5%(P<.0001),男性存在死亡率特异的过度入组(P=.001)。
- 白人、亚裔、黑人和西班牙裔分别占试验参与者的91.7%、1.5%、2.6%和1.7%。
- 与死亡率相比,黑人入组为预期死亡率的47%(P=.008),西班牙裔为17%(P<.001),亚裔为33%(P<.001),均低于白人(预期死亡率的114%,P<.001)。
- 达到既定种族入组基准的临床试验有少数族裔作者参与。
临床怎么用
- 作者认为本研究为临床试验入组工作提供了框架,并就与医疗服务不足患者入组相关的劳动力考量提供了指导。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The NIH Revitalization Act, implemented 29 years ago, set to improve the representation of women and minorities in clinical trials. In this study, we investigate progress made in all phase therapeutic clinical trials for neuroepithelial CNS tumors stratified by demographic-specific age-adjusted disease incidence and mortality. Additionally, we identify workforce characteristics associated with clinical trials meeting established accrual benchmarks. METHODS: Registry study of published clinical trials for World Health Organization defined neuroepithelial CNS tumors between January 2000 and December 2019. Study participants were obtained from PubMed and ClinicalTrials.gov. Population-based data originated from the CBTRUS for incidence analyses. SEER-18 Incidence-Based Mortality data was used for mortality analysis. Descriptive statistics, Fisher exact, and χ 2 tests were used for data analysis. RESULTS: Among 662 published clinical trials representing 49 907 participants, 62.5% of participants were men and 37.5% women (P < .0001) representing a mortality specific over-accrual for men (P = .001). Whites, Asians, Blacks, and Hispanics represented 91.7%, 1.5%, 2.6%, and 1.7% of trial participants. Compared with mortality, Blacks (47% of expected mortality, P = .008), Hispanics (17% of expected mortality, P < .001) and Asians (33% of expected mortality, P < .001) were underrepresented compared with Whites (114% of expected mortality, P < .001). Clinical trials meeting accrual benchmarks for race included minority authorship. CONCLUSIONS: Following the Revitalization Act, minorities and women remain underrepresented in therapeutic clinical trials for neuroepithelial tumors, relative to disease incidence and mortality. Study accrual has improved with time. This study provides a framework for clinical trial accrual efforts and offers guidance regarding workforce considerations associated with enrollment of underserved patients.
引用
- Reihl SJ, Patil N, Morshed RA, et al. A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act. Neuro Oncol. 2022. PMID: 34999844. doi:10.1093/neuonc/noac011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。